Investment, Funding & Disinvestments

CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.

Once fully operational, the hub is expected to enable access to treatment for more than 2.6 million patients across a population of more than 1 billion people.

The report estimates that improved interventions could help over 1.2 million adults transition out of obesity by 2031.

Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

Kenya aligned its position with the African regional statement presented by Zimbabwe on behalf of the WHO African Region, reinforcing a continent-wide call for equity at the heart of global health governance and emergency response.

Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.

Yuhan operates two API manufacturing facilities in South Korea and has reported steady international growth, with overseas sales increasing 21% in the first quarter.

The acquisition reflects a long-term strategic collaboration between the two companies, with Artivion already serving as the exclusive distributor of NEXUS across Europe, the Middle East, and Africa since 2019.

Owen Mumford brings established expertise in device design, precision moulding, and medical device assembly, which will now be integrated with Embecta’s commercial infrastructure and large-scale manufacturing capabilities.

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.